We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Dr. Pablo Mir. Movement Disorders Unit, Department of Neurology and Clinical Neurophysiology, Institute of Biomedicine of Seville, Hospital Universitario Virgen del Rocío/University of Seville/CSIC/CIBERNED, Seville, Spain- Biomedical Research Network Center on Neurodegenerative Diseases (CIBERNED), Carlos III Health Institute, Madrid, Spain - Department of Medicine, Faculty of Medicine, University of Seville, Seville, Spain.
Abstract Parkinson’s disease (PD) is one of the most common neurodegenerative disorders, with neuroinflammation playing a significant role in its etiology and progression. Both central and peripheral immune responses are involved, and evidence suggests a brain-periphery interaction in PD. Changes in leukocyte subpopulations have been observed in PD patients, making the neutrophil-to-lymphocyte ratio (NLR) a relevant marker of peripheral inflammation. Patients with PD have a higher NLR compared to healthy controls, indicating increased peripheral inflammation. This higher NLR suggests that the neutrophil-to-lymphocyte ratio is a useful non-invasive biomarker of systemic inflammation in PD. The peripheral immune response differs among patients based on their genetic background, with those having sporadic and GBA-associated PD showing a higher NLR in contrast to those with LRRK2-associated PD. Furthermore, this elevated peripheral inflammation is associated with dopaminergic neurodegeneration, underscoring the importance of understanding inflammatory processes in the context of PD for better diagnostic and therapeutic strategies.
Host: Dr. Ariadna Laguna. Main researcher Neurodegenerative Diseases (VHIR)
Register here to attend by Zoom: https://gencat.zoom.us/j/94801616000
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.